New Ellis (NUWE) Q1 2026: Pediatrics Now 50% of U.S. Revenue as Cardiorenal Platform Expands

2026-05-12 | By EarningsIQ Research

New Ellis entered 2026 executing on a focused cardiorenal strategy, with pediatric revenue now comprising half of its U.S. business and a key acquisition expanding its clinical platform. Margin gains and disciplined cash management reflect foundational operational improvements, while leadership signals an innovation pipeline targeting both near-term adoption and long-term category leadership. Investors should watch for pediatric momentum and the rollout of next-generation monitoring solutions as the strategy shifts from reset to execution.

Summary

• Pediatric Growth Surges: Pediatrics now drives half of U.S. revenue, anchoring the company’s clinical and commercial focus.
• Platform Expansion in Motion: RendiaTek acquisition adds kidney monitoring capabilities, broadening the cardiorenal care continuum.
• Operational Discipline Tightens: Cash burn reduction plan and margin gains signal a shift from reset to sustained execution.

Business Overview

New Ellis develops and commercializes medical devices for the management of fluid overload and kidney-related conditions, primarily serving hospitals and critical care settings. Its flagship product, Aquadex, an extracorporeal ultrafiltration system, generates revenue through console sales and recurring circuit usage. The company is increasingly focused on the pediatric critical care segment, while expanding its platform into kidney function monitoring following its acquisition of RendiaTek.

Performance Analysis

Revenue rose 26% year-over-year, driven by increased console placements and a 15% uptick in recurring circuit sales. Pediatrics now accounts for roughly 50% of U.S. revenue, with the company’s pediatric footprint expanding to 47 centers, including leading children’s hospitals. Gross margin improved to 70.1%, up 14 percentage points, reflecting a mix of improved pricing, favorable product mix, and the transition to contract manufacturing at KDI, contract device manufacturer.

Operating expenses climbed to $6 million, primarily from expanded sales headcount and compensation tied to increased commercial activity. The net loss widened to $4.3 million, but management highlighted a plan to halve monthly cash burn by Q4 while maintaining investment in high-traction areas. The balance sheet remains debt-free with $2.2 million in cash and equivalents, and a $5 million private placement completed during the quarter adds capital flexibility.

• Pediatric Channel Now Core: Pediatric accounts represent the most significant and fastest-growing customer base, reinforcing the company’s clinical relevance in high-acuity settings.
• Recurring Revenue Strength: Circuit sales growth signals increasing utilization and adoption of Aquadex therapy.
• Margin Expansion: Gross margin improvement reflects operational discipline and a shift toward higher-value product mix.

Q1 results confirm that operational improvements are translating into measurable commercial traction, particularly in pediatrics and recurring circuit sales, while cost discipline and capital raises underpin the foundation for continued execution.

Executive Commentary

Strategic Positioning

1. Pediatric Leadership Anchors Commercial Focus

Pediatrics now comprises 50% of U.S. revenue, with adoption in 47 centers and six top-ranked children’s hospitals. This segment provides both near-term growth and a differentiated clinical franchise. The company is leveraging existing relationships and clinical credibility to build a durable pediatric innovation pipeline, including the Vivian pediatric CRRT system, continuous renal replacement therapy, and new IP for safety features.

2. Cardiorenal Platform Expansion via RendiaTek

The acquisition of RendiaTek, automated kidney function monitoring technology, extends New Ellis’ platform beyond fluid removal to proactive kidney health management. While U.S. market introduction is slated for 2027, the move positions the company to address a broader spectrum of cardiorenal patient needs and strengthens its clinical value proposition in critical care.

3. Operational Discipline and Cash Runway Management

Management is executing a cash burn reduction plan targeting a 50% decrease by Q4, while maintaining focus on high-traction areas. This is paired with a $5 million capital raise and a continued commitment to gross margin consistency, ensuring resource allocation aligns with strategic priorities. The shift to contract manufacturing and pricing discipline have already delivered margin expansion.

4. Strengthened Leadership and Field Execution

Board and executive changes, including a new CFO and experienced directors, bring deeper healthcare and capital markets expertise. The return of top-performing sales leaders and targeted territory expansion, especially in South Texas and the Northeast, bolster field execution and customer coverage. These moves are designed to accelerate utilization growth in priority accounts.

Key Considerations

This quarter marks a critical inflection as New Ellis transitions from structural reset to execution, with pediatric momentum and platform expansion at the center of its strategy. Investors should weigh the durability of pediatric growth, integration of new technologies, and the sustainability of operational improvements.

Key Considerations:

• Pediatric Adoption as a Strategic Moat: Sustained growth in pediatric centers could provide insulation from broader market volatility and create a high-barrier niche.
• Execution Risk on RendiaTek Integration: The real impact of the acquisition will depend on successful development and launch of next-gen kidney monitoring solutions in 2027.
• Cash Burn and Capital Allocation: The ability to halve cash burn while maintaining growth investments will be critical to extending runway and avoiding dilutive capital raises.
• Sales Force Productivity: Expansion into new territories and the return of high-performing reps should accelerate account penetration, but requires ongoing performance management.

Risks

Key risks center on the pace of pediatric adoption, execution on the RendiaTek product roadmap, and the company’s ability to manage cash burn without sacrificing growth momentum. Any delays in the U.S. rollout of new kidney monitoring technology or a slowdown in pediatric utilization could pressure both revenue and investor confidence. Competitive responses from larger medtech players targeting the same care continuum also warrant monitoring.

Forward Outlook

For Q2 and the remainder of 2026, New Ellis management highlighted:

• Continued focus on pediatric account expansion and utilization growth
• Progress on RendiaTek product development with U.S. launch targeted for 2027
• Execution of a cash burn reduction plan aiming for a 50% decrease by Q4

Full-year guidance was not specifically quantified, but management reiterated priorities around capital discipline, commercial execution, and innovation pipeline advancement.

• Management expects pediatric and recurring revenue to remain primary growth engines
• Integration and development of new kidney monitoring technologies are slated to drive platform expansion opportunities

Takeaways

The quarter underscores New Ellis’ transition from strategic reset to focused execution, with pediatrics and cardiorenal platform expansion emerging as key long-term value drivers.

• Pediatric Growth Validates Strategy: The rapid rise of pediatric revenue and clinical adoption signals a defensible growth engine and a foundation for future innovation.
• Platform Expansion Sets Up Next Leg: RendiaTek’s integration and the push into automated kidney monitoring position New Ellis to address broader clinical needs and differentiate its offering.
• Watch for Execution on Cash Burn and New Product Rollouts: Investors should track the company’s ability to balance disciplined spending with continued commercial momentum and timely delivery of new solutions.

Conclusion

New Ellis’ Q1 results reflect tangible progress in operational discipline, pediatric market penetration, and strategic platform expansion. The company is now positioned for a period of focused execution, but sustained success will depend on delivering innovation, managing cash, and deepening its clinical foothold in high-need segments.

Industry Read-Through

The surge in pediatric adoption and focus on cardiorenal continuum solutions signal a broader trend in medtech toward specialization and integrated care platforms. Competitors in the fluid management and kidney monitoring space will likely need to accelerate innovation and clinical partnerships to keep pace. The shift to recurring revenue models via disposables, as seen in Aquadex circuit sales, reinforces the value of installed base expansion and utilization-driven growth. For investors, New Ellis’ trajectory highlights the importance of high-acuity, niche market focus as a lever for durable differentiation in an increasingly crowded medtech landscape.

NUWE Healthcare Medical Devices Pediatrics Cardiorenal Platform Expansion Recurring Revenue Innovation